Bumper Offer - Urjas oil Just @ Rs. 1
Oxalgin Nano Gel 30gm is a commercial drug that is prescribed in the form of Gel. Muscle Pain, Toothache, Rheumatic Pain are some of its major therapeutic uses. Other than this, Oxalgin Nano Gel 30gm has some other therapeutic uses, which have been discussed ahead.
The right dosage of Oxalgin Nano Gel 30gm depends on the age, gender, and medical history of the patient. Individual symptoms and route of administration also determines the right dosage. Detailed information has been provided in the dosage section.
Besides the aforementioned side effects, there are other adverse effects of Oxalgin Nano Gel 30gm as well, which are listed below. These side effects of Oxalgin Nano Gel 30gm are usually temporary and subside with the completion of treatment. If, however, they worsen or do not go away, please speak with your physician.
Oxalgin Nano Gel 30gm's effect during pregnancy is Severe and Mild while nursing. Warnings related to Oxalgin Nano Gel 30gm's effects on the liver, heart and kidney, if any, have been listed below.
Oxalgin Nano Gel 30gm is contraindicated in people with pre-existing medical conditions like Stomach Infection, Skin Rash, Stroke as it can result in adverse effects. The section on Oxalgin Nano Gel 30gm contraindications lists all such conditions.
Additionally, Oxalgin Nano Gel 30gm may also adversely react with other medicines. See below for a complete list.
Along with the above-mentioned precautions, remember that taking Oxalgin Nano Gel 30gm is considered safe while driving, and is addictive.
Oxalgin Nano Gel 30gm is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
Based on research, the following side effects have been observed when Oxalgin Nano Gel 30gm is used -
Severe
Moderate
Mild
Is the use of Oxalgin Nano Gel 30gm safe for pregnant women?
Oxalgin shows severe side effect on pregnant women. For this reason, pregnant women should only take it after taking medical advice.
Is the use of Oxalgin Nano Gel 30gm safe during breastfeeding?
Breastfeeding women can take Oxalgin as it bears very minor side effects for them.
What is the effect of Oxalgin Nano Gel 30gm on the Kidneys?
Use of Oxalgin may be dangerous for kidney. Do not use it without doctor advice.
What is the effect of Oxalgin Nano Gel 30gm on the Liver?
Use of Oxalgin may be dangerous for the liver. Do not use it without doctor's advice.
What is the effect of Oxalgin Nano Gel 30gm on the Heart?
Oxalgin can have moderate side effects on the heart. If you notice any harmful effects then stop taking this drug right away. Consult your doctor before using this medicine again.
Oxalgin Nano Gel 30gm should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Oxalgin Nano Gel 30gm unless your doctor advises you to do so -
Is this Oxalgin Nano Gel 30gm habit forming or addictive?
Oxalgin Nano Gel 30gm is not addictive in nature.
Is it safe to drive or operate heavy machinery when consuming?
Oxalgin Nano Gel 30gm will not make you feel sleepy or drowsy. So you drive or operate machinery safely.
Is it safe?
Yes, but take Oxalgin Nano Gel 30gm only as per medical advice.
Is it able to treat mental disorders?
There is no benefit of taking Oxalgin Nano Gel 30gm for mental disorders.
Interaction between Food and Oxalgin Nano Gel 30gm
Due to the absence of research, it is difficult to say how Oxalgin Nano Gel 30gm and food will interact.
Interaction between Alcohol and Oxalgin Nano Gel 30gm
Consult your doctor before consuming alcohol while taking Oxalgin Nano Gel 30gm as it can have severe side effects.
This medicine data has been created by -
References
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 427-429
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 204
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Voltaren® (diclofenac sodium)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Diclofenac (diclofenac sodium)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Solaraze® (diclofenac sodium)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 427-429
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 204
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Voltaren® (diclofenac sodium)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Diclofenac (diclofenac sodium)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Solaraze® (diclofenac sodium)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 427-429
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 204
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Voltaren® (diclofenac sodium)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Diclofenac (diclofenac sodium)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Solaraze® (diclofenac sodium)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 427-429
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 204
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Voltaren® (diclofenac sodium)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Diclofenac (diclofenac sodium)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Solaraze® (diclofenac sodium)
